NCT05482269 Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography
| NCT ID | NCT05482269 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shengjing Hospital |
| Condition | Pulmonary Embolism and Thrombosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2011-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2011-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators aim to build a predictive tool for Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography.
Eligibility Criteria
Inclusion Criteria: * age of ≥ 18 years and a pulmonary embolism diagnosis based on CT pulmonary angiography Exclusion Criteria: * pregnancy * reception of reperfusion treatment before admission * missing data regarding CT parameters, echocardiography, cardiac troponin I (c-Tn I), and N-terminal-pro brain natriuretic peptide (NT-pro BNP) levels.
Contact & Investigator
DONG JIA
PRINCIPAL INVESTIGATOR
Shengjing Hospital
Frequently Asked Questions
Who can join the NCT05482269 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Embolism and Thrombosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05482269 currently recruiting?
Yes, NCT05482269 is actively recruiting participants. Contact the research team at jiadong0101@126.com for enrollment information.
Where is the NCT05482269 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT05482269 clinical trial?
NCT05482269 is sponsored by Shengjing Hospital. The principal investigator is DONG JIA at Shengjing Hospital. The trial plans to enroll 2,000 participants.